Literature DB >> 11745284

Priming prostate carcinoma cells for increased apoptosis is associated with up-regulation of the caspases.

R N Coffey1, R W Watson, P K Hegarty, C L Watson, L Wolohan, H R Brady, C O'Keane, J M Fitzpatrick.   

Abstract

BACKGROUND: The potential to prime prostatic carcinoma cell lines for apoptosis represents an exciting strategy for the treatment of patients with this disease. The ability and the underlying molecular mechanisms involved in sensitizing both androgen-sensitive and androgen-insensitive cell types to a range of apoptotic-inducing agents are investigated by the authors.
METHODS: Primary and secondary cell lines were pretreated with diethyl-maleate (DEM) prior to the induction of apoptosis by Fas antibody (1 microg/mL), cycloheximide (1 microg/mL), etoposide (62.5 microM), and radiation (5 grays). It was demonstrated previously that DEM (50 microM) increases the sensitivity to apoptosis induced by these agents. The effects of DEM on both protein and RNA expression was determined by Western blot analysis and a ribonuclease protection assay, respectively. The effects of DEM on intracellular glutathione (GSH) levels and its intracellular distribution also were assessed.
RESULTS: DEM did not affect the expression of the caspases at the transcriptional level but was associated with increased procaspase-3 and caspase-8 protein levels. DEM preincubation restored sensitivity to Fas antibody and radiation-induced apoptosis in cells from the LNCaP-bcl-2 transfectant cell line that, normally, are resistant to these apoptotic stimuli. It is that DEM chemically depletes intracellular thiol levels. Although no depletion in total intracellular thiol GSH was observed at these concentrations of DEM, trafficking of GSH from the nucleus to the cytosol was demonstrated.
CONCLUSIONS: Identification of the caspases as a potential target for chemical manipulation may serve as an effective, adjuvant-based approach in the treatment of patients with prostate carcinoma and, in particular, for immunotherapy and radiation-based strategies that rely on the activation of these death-effector proteases. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11745284     DOI: 10.1002/1097-0142(20011101)92:9<2297::aid-cncr1576>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Anticancer activity of a cyclooxygenase inhibitor, CX9051, in human prostate cancer cells: the roles of NF-kappaB and crosstalk between the extrinsic and intrinsic apoptotic pathways.

Authors:  Chiung-Hua Huang; Jih-Hwa Guh; Grace Shiahuy Chen; Pin-Hsuan Lu; Ji-Wang Chern
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-06-08       Impact factor: 3.000

2.  Antisense Bcl-2 sensitizes prostate cancer cells to radiation.

Authors:  Zhaomei Mu; Paul Hachem; Alan Pollack
Journal:  Prostate       Date:  2005-12-01       Impact factor: 4.104

3.  Oxidative stress adaptation in aggressive prostate cancer may be counteracted by the reduction of glutathione reductase.

Authors:  Mariana Freitas; Inês Baldeiras; Teresa Proença; Vera Alves; Anabela Mota-Pinto; Ana Sarmento-Ribeiro
Journal:  FEBS Open Bio       Date:  2012-05-30       Impact factor: 2.693

4.  Cold Atmospheric Plasma Treatment Induces Anti-Proliferative Effects in Prostate Cancer Cells by Redox and Apoptotic Signaling Pathways.

Authors:  Martin Weiss; Denis Gümbel; Eva-Maria Hanschmann; Robert Mandelkow; Nadine Gelbrich; Uwe Zimmermann; Reinhard Walther; Axel Ekkernkamp; Axel Sckell; Axel Kramer; Martin Burchardt; Christopher H Lillig; Matthias B Stope
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

5.  Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells.

Authors:  Tae-Jin Lee; Oliver Sartor; Ronald B Luftig; Shahriar Koochekpour
Journal:  Mol Cancer       Date:  2004-11-17       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.